USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: PROMEGA CORP.
City: Madison
State: WI
Zip+4: 53711
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,406,047.00 17
SBIR Phase II $3,733,264.00 6

Award List:

SITE-SPECIFIC ENDONUCLEASES FOR HUMAN GENOME MAPPING

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: DOE
Principal Investigator: Dr Robery Lowery , Principal Investigator
Award Amount: $50,000.00

SITE-SPECIFIC ENDONUCLEASES FOR HUMAN GENOME MAPPING

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: DOE
Principal Investigator: Dr Robery Lowery , Principal Investigator
Award Amount: $500,000.00
Abstract:
A major limitation in current large scale genome mapping methodology is that few tools exist for generating specific dna fragments in the megabase size range. this phase i research is examining the feasibility of developing a familyof intron-encoded site-specific endonucleases capable of generating… More

MODIFIED SITE-SPECIFIC ENDONUCLEASE FOR GENOME RESEARCH

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert G Lowery
Award Amount: $50,000.00
Abstract:
With the rapid growth of human genome research, there is a growing need for advanced mapping and sequencing methods. in current methodology, there is no single step process for generating specific dna fragments in the megabase size range. promega will undertake random mutagenesis coupled with a… More

INHIBITING TUMOR GROWTH BY RNASIN RIBONUCLEASE INHIBITOR

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Terry Riss
Award Amount: $50,000.00
Abstract:
An increasing number of recent tumor growth studies have focused on inhibition of angiogenesis as a means of preventing tumor metastasis. as a result, several anti-angiogenic agents have been described, including placental ribonuclease inhibitor. preliminary research completed by promega corporation… More

Novel Beetle Luciferases for Biomedical Development

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Keith V. Wood
Award Amount: $73,827.00

USING MULTIPLEXED LUMINESCENCE TO EXTEND BIOASSAY CAPABILITIES

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: NSF
Principal Investigator: Keith V Wood
Award Amount: $50,000.00

Real-Time Multiplexed Signal Transduction in Microbial Environmental Sensors

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency / Branch: DOD / DARPA
Principal Investigator: Keith Wood
Award Amount: $99,923.00
Abstract:
Biologically relevant environmental monitoring can be achieved using the genetic responses of microbes to environment conditions as sensors, particularly the specific and generalized responses to toxicity. The generalized toxicity response may be especially improtant when prior knowledge of the type… More

Novel Polymorphic Markers for Genetic Analyses

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: James Schumm
Award Amount: $76,051.00

Novel Beetle Luciferases for Biomedical Development

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: HHS
Principal Investigator: Keith V. Wood
Award Amount: $737,548.00
Abstract:
Though radioactivity is widely used in bioassays due to its high sensitivity and convenience, safety and environmental concerns have accelerated efforts to eliminate its use. Recent procedures using luminescence have often surpassed conventional isotopic methods; among these the luminescence of… More

Developing Technologies for Studying Protein Prenylation

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Erik Schaefer
Award Amount: $98,782.00
Abstract:
Prenylation (the modification of proteins with the cholesterol biosynthesis intermediates C(15) fargeranylgeranyl) is a newly discovered postranslational modification that targets certain proteins tointerior of the cell, thereby regulating their biological activity. The best studied example… More

Novel Polymorphic Markers for Genetic Analyses

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: HHS
Principal Investigator: James Schumm
Award Amount: $700,918.00
Abstract:
Our research will identify and develop a new type of polymorphic DNA marker that will allowsimplification and acceleration of genetic analyses. These multiplex-compatible amplifiable markers willhave the advantage of simplified analysis versus current PCR-based marker systems, allowing detectionin a… More

RIBONUCLEASE INHIBITORS

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $99,384.00

An Engineered RNA/DNA Polymerase to Increase Speed and Economy of DNA Sequencing

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: DOE
Principal Investigator: Dr. Mark W. Knuth , Scientific Manager, R & D
Award Amount: $75,000.00

USING MULTIPLEXED LUMINESCENCE TO EXTEND BIOASSAY CAPABILITIES

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: NSF
Principal Investigator: Keith V Wood
Award Amount: $299,328.00
Abstract:
Current luminescence bioassays rely solely upon mesurement of luminescence intensity to generate information. multiple colors from beetle luciferase has created the opportunity to increase assay information content by using multiplexing techniques to measure light intensities at different… More

The Design and Synthesis of Orally Active Inhibitors of Botilinum Toxin metalloproteases

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Alexey G. Zdanovsky
Award Amount: $99,892.00
Abstract:
This proposal describes strategies to synthesize potent inhibitors of botulinum neurotoxin metalloproteases. These metalloproteases [BoTx protease] have been shown to be the molecular effectors of the paralytic effects of these toxins. Mechanism-based drug design will be applied to develop… More

An Engineered RNA/DNA Polymerase to Increase Speed and Economy of DNA Sequencing

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: DOE
Principal Investigator: Dr. Mark W. Knuth , Scientific Manager, R & D
Award Amount: $750,000.00
Abstract:
41294 November 19, 1996 Promega Corporation DNA sequence information is the cornerstone for considerable experimental design and analysis in the biological sciences, but it is time consuming and expensive. The project will focus on advancing DNA… More

NEW APPROACH TO RAPID AND SENSITIVE DNA QUANTITATION

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Shultz, john w
Award Amount: $99,990.00

DRUG DISCOVERY BY RAPID QUANTITATION IN LIVING CELLS

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Wood, keith v
Award Amount: $93,913.00

TOOLS FOR STUDYING EUKARYOTIC CELL MEMBRANE TRAFFICKING

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Zdanovsky, alexey g
Award Amount: $99,327.00

NOVEL DETECTION METHODOLOGY FOR LYME DISEASE TARGETS

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lesley, scott a
Award Amount: $100,000.00

The Design and Synthsis of Orally Active Inhibitors of Botulinum Toxin Metalloproteases

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency / Branch: DOD / ARMY
Principal Investigator: Alexey G. Zdanovsky
Award Amount: $745,470.00
Abstract:
This proposal describes strategies to synthesize potent inhibitors of botulinum neurotoxin metalloproteases. These metalloproteases [BoTx protease] have been shown to be the molecular effectors of the paralytic effects of these toxins. Mechanism-based drug design will be applied to develop… More

The Design and Construction of Botulinum Toxin Drug Delivery Vehicles

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Dr. Alexey G. Zdanovsky
Award Amount: $99,157.00
Abstract:
This proposal describes strategies to develop a neural cell specific delivery vehicle system which utilizes the target specificity of the botulinum toxin family to provide a generic platform for the delivery of drugs to the neuronal cytosol. Using a multi-disciplinary approach, we will construct and… More

DETECTION METHOLOGY FOR MYCOBACTERIA TUBERCULOSIS

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Haak-frendscho, Mary
Award Amount: $90,801.00